What is Wellbutrin?
The Food and Drug Administration first approved Wellbutrin as an antidepressant in 1985. Since it's initial approval, research regarding Wellbutrin, manufactured by GlaxoSmithKline, has revealed a possible link between the drug's side effects and child birth defects in mothers who took the drug during early in their pregnancy term.
A study published in the American Journal of Obstetrics & Gynecology suggests that mothers who took Wellbutrin or Zyban early in their pregnancy more than double the risk of having a baby with heart defects. Such childbirth defects are known as left outflow defects, affecting the blood flow of the heart from the heart's left chambers to the rest of the body. While the defect is considerably rare, the study suggests the risks of the defect were increased from the anti-depressant.
In addition to left outflow heart defect other serious birth defects include: Heart Ventricle Outflow Track defect, Atrial Septal defect, A Ventrical Septal defect, Persistent Pulmonary Hypertension, Pulmonary Stenosis, as well as other possible defects including the lungs.
|